Viking Therapeutics Emerges as Key Player in Weight-Loss Drug Market

Viking Therapeutics has captured significant market attention with its recent stock performance, demonstrating strong upward momentum following analyst confirmation of what they describe as a “substantial price surge.” The biopharmaceutical company’s shares closed at $27.88 on Thursday, marking a solid 1.86 percent gain.

The company’s metabolic disorder pipeline is generating considerable excitement, particularly its lead obesity candidate VK2735. Recent corporate updates from October 1 revealed important developmental milestones. The Phase 3 VANQUISH registration program for the injectable formulation is already underway, while the Phase 2 VENTURE trial for an oral tablet version has successfully achieved its primary endpoint.

This dual-approach strategy—offering both injectable and oral formulations—positions Viking competitively in the rapidly expanding weight-loss medication sector. Further expanding its metabolic portfolio,... Read more...